Keyphrases
Atopic Dermatitis
94%
Infantile Hemangioma
81%
Endothelial Cells
66%
Pediatric Patients
63%
Psoriasis
49%
Melanoma Cells
47%
Hemangioma
43%
Cutaneous Leishmaniasis
42%
Melanoma
40%
Methotrexate
39%
Tumor
39%
Stem Cells
39%
Israel
39%
Pediatric Population
38%
Systemic Administration
37%
Melanosome
37%
Sirolimus
37%
Pediatric
36%
Clinical Characteristics
35%
Leishmania Tropica
33%
Whole Exome Sequencing
33%
Endothelin-1 (ET-1)
31%
Lung Metastasis
31%
Mastocytosis
30%
Angiogenesis
29%
Apoptosis
27%
Vascular Endothelial Growth Factor
27%
MicroRNA
27%
Ultraviolet-B (UV-B)
26%
Immunodeficiency
26%
Novel mutation
25%
Vascular Wall
25%
Keratinocytes
25%
Pemphigus
25%
Transdifferentiation
25%
NRAS mutation
25%
Tuberous Sclerosis
25%
Chronic Urticaria
25%
Tuberous Sclerosis Complex
25%
Herpes Simplex Virus Thymidine Kinase
25%
Graft-versus-host Disease (GvHD)
25%
Double-stranded RNA
25%
RNA Editing
25%
Lymphatic Malformation
25%
Single-center Experience
25%
Gene Therapy
23%
Metastasis
22%
Corticosteroids
22%
Antiangiogenic
22%
Clinical Presentation
22%
Medicine and Dentistry
Pediatrics
100%
Disease
92%
Retrospective Study
64%
Neoplasm
60%
Pediatrics Patient
58%
Capillary Hemangioma
55%
Hemangioma
51%
Rapamycin
50%
Nodular Melanoma
46%
Cutaneous Leishmaniasis
43%
Stem Cell
41%
Promoter Region
40%
Endothelial Cell
38%
Urticaria
37%
Atopic Dermatitis
37%
Melanoma Cell
37%
Mastocytosis
32%
Systemic Therapy
32%
Exome Sequencing
31%
In Vitro
30%
Chronic Urticaria
30%
Disease Course
29%
Infection
29%
Metastatic Carcinoma
28%
Congenital Malformation
28%
Melanosome
28%
microRNA
26%
Topical Treatment
26%
Angiogenesis
26%
Pemphigus
25%
Primary Tumor
25%
Herpes Simplex Virus
25%
Tuberous Sclerosis
25%
Psoriasis
25%
Leishmania tropica
25%
Thymidine Kinase
25%
Systemic Administration
25%
Lymphangiomatosis
25%
Immune Deficiency
25%
Side Effect
22%
Lymphatic Anomaly
21%
Colony Forming Cell
21%
Lymph Duct
20%
Mast Cell
20%
Leishmania Major
20%
Dermatitis
19%
Hormone Determination
18%
Antiangiogenic Gene Therapy
18%
Mesenchymal Stem Cell
18%
Adverse Event
18%